Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 12788999)


Breast and ovarian cancer.

Wooster R, Weber BL.

N Engl J Med. 2003 Jun 5;348(23):2339-47. Review. No abstract available.


Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.

Walker LC, Waddell N, Ten Haaf A; kConFab Investigators, Grimmond S, Spurdle AB.

Breast Cancer Res Treat. 2008 Nov;112(2):229-36. Epub 2007 Dec 20.


The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.

Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Díez O, Alonso MC, Lazaro C, Blanco I, Sánchez-de-Abajo A, Caldés T, Blanco A, Graña B, Durán M, Velasco E, Chirivella I, Cardeñosa EE, Tejada MI, Beristain E, Miramar MD, Calvo MT, Martínez E, Guillén C, Salazar R, San Román C, Antoniou AC, Urioste M, Benítez J.

Clin Cancer Res. 2008 May 1;14(9):2861-9. doi: 10.1158/1078-0432.CCR-07-4436.


BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.

Antoniou AC, Durocher F, Smith P, Simard J, Easton DF; INHERIT BRCAs program members.

Breast Cancer Res. 2006;8(1):R3. Epub 2005 Dec 12.


Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.

King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group.

Science. 2003 Oct 24;302(5645):643-6.


One risk fits all?

De Bock GH, Mourits MJ, Oosterwijk JC.

J Clin Oncol. 2007 Aug 1;25(22):3383-4; author reply 3384. No abstract available.


Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan.

Liede A, Malik IA, Aziz Z, Rios Pd Pde L, Kwan E, Narod SA.

Am J Hum Genet. 2002 Sep;71(3):595-606. Epub 2002 Aug 13.


Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.

Finch A, Metcalfe K, Lui J, Springate C, Demsky R, Armel S, Rosen B, Murphy J, Elit L, Sun P, Narod S.

Clin Genet. 2009 Mar;75(3):220-4.


Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.

Gallardo M, Silva A, Rubio L, Alvarez C, Torrealba C, Salinas M, Tapia T, Faundez P, Palma L, Riccio ME, Paredes H, Rodriguez M, Cruz A, Rousseau C, King MC, Camus M, Alvarez M, Carvallo P.

Breast Cancer Res Treat. 2006 Jan;95(1):81-7. Epub 2005 Oct 27.


[Clinical and molecular diagnosis of inherited breast-ovarian cancer].

Chompret A.

J Gynecol Obstet Biol Reprod (Paris). 2003 Apr;32(2):101-19. Review. French.


Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.

Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Australian Ovarian Cancer Study Management Group.

J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. doi: 10.1093/jnci/djn345. Epub 2008 Oct 28.


Susceptibility to breast cancer: hereditary syndromes and low penetrance genes.

Nusbaum R, Vogel KJ, Ready K.

Breast Dis. 2006-2007;27:21-50. Review.


Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.

Martin AM, Blackwood MA, Antin-Ozerkis D, Shih HA, Calzone K, Colligon TA, Seal S, Collins N, Stratton MR, Weber BL, Nathanson KL.

J Clin Oncol. 2001 Apr 15;19(8):2247-53.


Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.

Meindl A; German Consortium for Hereditary Breast and Ovarian Cancer.

Int J Cancer. 2002 Feb 1;97(4):472-80.


The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.

Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, Warner E, Olopade O, Eisen A, Weber B, McLennan J, Sun P, Narod SA.

Gynecol Oncol. 2005 Jan;96(1):222-6.


BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.

Einbeigi Z, Enerbäck C, Wallgren A, Nordling M, Karlsson P.

Acta Oncol. 2010 Apr;49(3):361-7. doi: 10.3109/02841860903521095.


Identifying and managing hereditary risk of breast and ovarian cancer.

Frank TS, Critchfield GC.

Clin Perinatol. 2001 Jun;28(2):395-406. Review.


Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.

Wolff TA, Wilson JE.

Am Fam Physician. 2006 Nov 15;74(10):1759-60. Review. No abstract available.


BRCA1 and BRCA2 cancer risks.

Antoniou AC, Pharoah PD, Easton DF, Evans DG.

J Clin Oncol. 2006 Jul 10;24(20):3312-3; author reply 3313-4. No abstract available.


BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.

Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G.

J Clin Oncol. 2002 Jun 1;20(11):2701-12.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk